• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002; 3: 3038.
  • 3
    Bajaj M, Defronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 2003; 10: 31123.
  • 4
    Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 290310.
  • 5
    Somasundar P, Frankenberry KA, Skinner H, Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM, Vona-Davis LC. Prostate cancer cell proliferation is influenced by leptin. J Surg Res 2004; 118: 7182.
  • 6
    DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 31868.
  • 7
    Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 10718.
  • 8
    Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194202.
  • 9
    Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 14752.
  • 10
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005; 103: 7684.
  • 11
    Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, Olsson T. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001; 86: 13415.
  • 12
    Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004; 63: 2538.
  • 13
    Hsing AW, Chua S,Jr, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93: 7839.
  • 14
    Thomas T, Burguera B, Melton LJ,III, Atkinson EJ, O'Fallon WM, Riggs BL, Khosla S. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000; 49: 127884.
  • 15
    Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, Fucker K, Julius U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002; 39: 10510.
  • 16
    Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H, Stenman UH, Jellum E, Olsson T. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 4745.
  • 17
    Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998; 76: 258.
  • 18
    Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol 2006; 28: 73745.
  • 19
    Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 191017.
  • 20
    Stattin P, Kaaks R. Re: Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 10867. author reply 7.
  • 21
    Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T, Stenman UH, Riboli E, Hallmans G, Stattin P. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003; 12: 30915.
  • 22
    Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellstrom M, Hugosson J, Lundgren R, Stattin P, Tornblom M, Johansson JE. The national prostate cancer register in Sweden 1998–2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 11723.
  • 23
    SobinLH, WittekindCL, eds. UICC TNM classification of malignant tumours, 6th edn. New York: Wiley, 2002.
  • 24
    Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 148795.
  • 25
    SAS Institute. SAS/STAT User's guide, version 9.1, Cary, NC, 2004.
  • 26
    World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation, Part 1: The problem of overweight and obesity. Geneva: World Health Organisation, 2000.
  • 27
    World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation, 1999.
  • 28
    Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004; 109: 14952.
  • 29
    Hovorka R, Jones RH. How to measure insulin secretion. Diabetes Metab Rev 1994; 10: 91117.
  • 30
    Hsing AW, Gao YT, Chua S,Jr, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 6771.
  • 31
    Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 59.
  • 32
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 162538.
  • 33
    Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 34553.
  • 34
    Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 43945.
  • 35
    Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174: 91922.
  • 36
    MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 9891003.
  • 37
    Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003; 89: 123742.
  • 38
    Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003; 95: 12404.
  • 39
    Oterdoom LH, de Vries AP, van Son WJ, van der Heide JJ, Ploeg RJ, Gansevoort RT, de Jong PE, Gans RO, Bakker SJ. Validation of insulin resistance indexes in a stable renal transplant population. Diabetes Care 2005; 28: 24249.
  • 40
    McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 4604.
  • 41
    Rolandsson O, Marklund SL, Norberg M, Agren A, Hagg E. Hemoglobin A1c can be analyzed in blood kept frozen at −80°C and is not commonly affected by hemolysis in the general population. Metabolism 2004; 53: 14969.
  • 42
    Peacock I. Glycosylated haemoglobin: measurement and clinical use. J Clin Pathol 1984; 37: 84151.
  • 43
    Korbonits M, Trainer PJ, Little JA, Edwards R, Kopelman PG, Besser GM, Svec F, Grossman AB. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin Endocrinol (Oxf) 1997; 46: 7517.
  • 44
    Baumgartner RN, Waters DL, Morley JE, Patrick P, Montoya GD, Garry PJ. Age-related changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat. Metabolism 1999; 48: 37884.
  • 45
    Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994; 43: 599603.
  • 46
    Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005; 23: 36877.
  • 47
    Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 2000; 3: 15772.
  • 48
    Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 21335.
  • 49
    Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 12629.
  • 50
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 8691.
  • 51
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 21524.
  • 52
    Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 134653.
  • 53
    Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004; 22: 310412.
  • 54
    Unden AL, Elofsson S, Knox S, Lewitt MS, Brismar K. IGF-I in a normal population: relation to psychosocial factors. Clin Endocrinol (Oxf) 2002; 57: 793803.
  • 55
    Frystyk J. Free insulin-like growth factors—measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 33775.
  • 56
    Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 3968495.
  • 57
    Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 2001; 17: 36373.